UK markets closed
  • NIKKEI 225

    29,018.33
    -272.68 (-0.93%)
     
  • HANG SENG

    28,558.59
    +121.75 (+0.43%)
     
  • CRUDE OIL

    70.73
    -1.42 (-1.97%)
     
  • GOLD FUTURES

    1,779.00
    -82.40 (-4.43%)
     
  • DOW

    33,829.13
    -204.54 (-0.60%)
     
  • BTC-GBP

    27,043.41
    -820.22 (-2.94%)
     
  • CMC Crypto 200

    933.39
    -36.49 (-3.76%)
     
  • ^IXIC

    14,166.12
    +126.44 (+0.90%)
     
  • ^FTAS

    4,071.33
    -17.14 (-0.42%)
     

How Much Is BioNTech's Increased Vaccine Production Really Worth?

·4-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BioNTech (NASDAQ: BNTX) recently raised guidance for the number of doses of its coronavirus vaccine that the biotech thinks it'll be able to produce this year. In this video from Motley Fool Live, recorded on April 5, Fool.com contributors Brian Orelli and Keith Speights discuss whether the increase will actually help the German drugmaker. Unfortunately, between a supply glut and the inability for developing companies to pay full price, the added capacity may not help BioNTech's bottom line that much.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting